p210 bcr/abl kinases inhibitors (Sidney Kimmel Cancer Center)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namep210 bcr/abl kinases inhibitors (Sidney Kimmel Cancer Center)
Drug Alias NameAC22 (Sidney Kimmel Cancer Center)K1P (Sidney Kimmel Cancer Center)AC19 (Sidney Kimmel Cancer Center)K1PAC22 +[6] 
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsAnticancer protein kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSidney Kimmel Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSidney Kimmel Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A